Document:

<PAGE>
                                                                   Exhibit 10.51

                                                            *** Text Omitted and
                                                                Filed Separately
                                                          Confidential Treatment
                                                                 Requested Under
                                                  17 C.F.R (S)(S) 200.80 (b)(4),
                                                            200.83 and 240.24b-2

                                  CONFIDENTIAL

                  RESEARCH COLLABORATION AND LICENSE AGREEMENT
                  --------------------------------------------

         This Research Collaboration and License Agreement (the "Agreement") is
made and entered into this 23rd day of August, 2001 (the "Effective Date") by
and between Sequenom, Inc., a company incorporated in the state of Delaware and
having a place of business at 3595 John Hopkins Court, San Diego, CA 92121
(hereinafter "SQNM") of the first part; and Glaxo Group Limited, a company
limited by shares incorporated in England and Wales, whose registered office is
at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, England,
and SmithKline Beecham Corporation, a Pennsylvania corporation having a place of
business at 709 Swedeland Road, King of Prussia, PA 19406 (hereinafter
collectively referred to as "GlaxoSmithKline" or "GSK") of the second part.

         WHEREAS, SQNM has developed its proprietary MassARRAY(TM) System (as
defined herein) and related products and technologies pertaining to nucleic acid
analysis by mass spectrometry; and

         WHEREAS, SQNM is engaged in genomics research and development, such as
the confirmation and characterization of putative public domain single
nucleotide polymorphisms (SNPs) using its intellectual property, know how,
information, and equipment including hardware, software and consumables
pertaining to the MassARRAY(TM) Technology and has certain intellectual property
related thereto; and

         WHEREAS, GSK is a pharmaceutical company engaged in research and
development (R&D) and utilizes genetic and genomic research in all phases of R&D
for purposes such as new target discovery, pharmacogenetics, pharmacogenomics to
support the commercialization of therapeutics for worldwide consumers; and

         WHEREAS, GSK desires to enter into this Agreement and engage SQNM to
perform with GSK a collaborative research project with the objective of
developing SNP assays ("Assays") on the terms set forth herein; and

         WHEREAS, the Parties both agree that this Agreement and the terms and
conditions contained herein are of mutual benefit in that the confirmation of
public domain SNPs, the development of Assays to determine allelic frequencies
in human DNAs, and the acquisition of quality oligonucleotide reagents at
reduced prices is of value to both Parties.

         NOW THEREFORE, in consideration of the premises and of the mutual
covenants and conditions hereinafter set forth, the Parties, intending to be
legally bound, hereby covenant and agree as follows:

                             ARTICLE I. DEFINITIONS

         For the purposes of the Agreement, the following words and phrases
shall have the following meanings, and the use of the singular form shall
include the plural form and vice versa:

                                       1

<PAGE>

                                  CONFIDENTIAL

1.   "Affiliate" means any corporation or other entity which controls, is
      ---------
     controlled by or is under common control with a party to this Agreement. A
     corporation or other entity, as applicable, shall be regarded as in control
     of another corporation or other entity if it owns or directly or indirectly
     controls at least fifty percent (50%) of the voting stock of the other
     corporation or (a) in the absence of the ownership of at least fifty
     percent (50%) of the voting stock of a corporation or (b) in the case of a
     non-corporate entity, if it possesses, directly or indirectly, the power to
     direct or cause the direction of the management and policies of such
     corporation or non-corporate entity, as applicable.

2.   "Allelotype" or "Allele Frequency Information" means a [...***...]
      ----------      ----------------------------

3.   "Background Data" means the pre-existing, proprietary data and information
      ---------------
     which is i) owned by one Party as of the Effective Date of this Agreement,
     and ii) related to the Project hereunder, and iii) provided by the owning
     Party to the other Party for use in the Project pursuant to this Agreement
     or are included within the scope of the options to licenses under Article
     IV.C. Notwithstanding the above, Background Data shall not include any data
     that is in the public domain. Background Data includes but is not limited
     to any gene-related or SNP-related sequence or other information provided
     from one Party to the other Party during the term of the Agreement which is
     not already in the public domain (i.e., publicly available and not
     protected by any proprietary rights).

4.   "Background Technology" means the pre-existing technology, inventions
      ---------------------
     and/or discoveries, whether or not patentable, which are i) owned by one
     Party as of the Effective Date of this Agreement, and ii) related to the
     Project hereunder, and iii) provided by the owning Party to the other Party
     for use in the Project pursuant to this Agreement or are included within
     the scope of the options to licenses under Article IV.C. In the case of
     SQNM, Background Technology includes but is not limited to the technology
     and items listed in Exhibits C1 and C2, and specifically includes U.S.
     Patent No. 6,258,538 and any patent applications claiming priority to or
     from the Patent and having an identical specification, and foreign
     equivalents and counterparts thereof claiming such technology, including
     any and all continuations, divisionals, reissues and reexaminations
     relating thereto (the "538 Patent"). Background Technology shall not
     include any technology, inventions and/or discoveries of a Party which are
     in the public domain, as defined above.

5.   "Confirmed SNP" shall mean a SNP for which a Functional Assay has revealed
      -------------
     the existence of a polymorphism (either high or low frequency) in the CEPH
     DNA [...***...].

6.   "Element" shall mean each of the three hundred eighty four (384)
      -------
     predetermined positions on the 384 SpectroCHIP(TM) DNA analysis chip for
     the location of reaction products for analysis by the MassARRAY(TM) System
     wherein the reaction products at each position are generated by exactly one
     monoplex or one multiplex MassEXTEND(TM) reaction performed on a DNA sample
     from a single person or organism and not from multiple people or organisms.
     By way of example, for the 384 SpectroCHIP(TM) DNA analysis chip, each chip
     contains three hundred eighty four (384) positions, so that for the
     MassARRAY(TM) System which is

                                               *Confidential Treatment Requested

                                        2

<PAGE>

                                  CONFIDENTIAL

     processing a chip that has a DNA sample from a single person at each
     position, three hundred eighty four (384) Elements are used and consumed
     under this definition.

7.   "Functional Assay" shall mean a Processed SNP Assay that satisfies
      ----------------
     parameters for quality and robustness as set forth in Exhibit A and
     exhibits at least one of the expected allelotypes in the CEPH panel of
     DNAs.

8.   "Gene-Based SNPs" means SNPs that reside in introns, exons, promoters, and
      ---------------
     other regulatory regions of genes.

9.   "Genotyping" means analyzing oligonucleotide or nucleic acid samples to
      ----------
     discover, test, confirm, or validate potential or known mutations or
     polymorphisms and identifying and characterizing mutations or polymorphisms
     as to genotype and/or allelotype.

10.  "GSK-nominated SNPs" means the set of [...***...] putative SNPs derived
      ------------------
     from [...***...] that are selected by GSK for inclusion in the work
     performed under this Agreement pursuant to the SOW as set forth in Exhibit
     A, all of which shall be different than the SQNM-nominated SNPs.

11.  "Know-How" means unpatented technical and other non-public or proprietary
      --------
     information including but not limited to unpublished patent applications,
     trade secrets, ideas, concepts, inventions, discoveries, data, formulae,
     specifications, techniques, procedures for experiments and other protocols,
     results of experimentation and assay protocols.

12.  "Intellectual Property Rights" means all proprietary legal rights owned or
      ----------------------------
     controlled by a Party with respect to the technology, discoveries and/or
     inventions of such Party, including all trade secrets, know-how,
     copyrights, trademarks, and patents (including inventor's certificates) and
     applications therefor throughout the world, and any other form of right by
     which a Party may effectively exclude another Party from making, having
     made, using, selling, offering for sale or importing such technology,
     discoveries and/or inventions, including contract rights.

13.  "GSK's Internal Research Purposes" means GSK's internal research and
      --------------------------------
     development purposes and activities, including, but not limited to
     [...***...] research and development purposes and activities. For the
     avoidance of doubt, Internal Research Purposes includes GSK's research and
     development activities that are being carried out by GSK [...***...]

14.  "SQNM's Internal Research Purposes" means SQNM's internal research and
      ---------------------------------
     development purposes and activities, including, but not limited to
     [...***...] research and development purposes and activities. For the
     avoidance of doubt, Internal Research Purposes includes SQNM's research and
     development activities that are being carried out by SQNM [...***...]

                                               *Confidential Treatment Requested

                                        3

<PAGE>

                                  CONFIDENTIAL

15.  "New IP" shall mean any and all inventions, discoveries, technology and
      ------
     Project Data, whether or not patentable, which are discovered or created in
     the course of performing the work described in the Statement of Work (SOW)
     for the Project as set forth in Exhibit A. By way of example and not by
     limitation, New IP shall include all Functional Assays, Processed SNP
     Assays, Allele Frequency Information and all inventions and discoveries
     related thereto, whether or not patentable, which are developed hereunder.

16.  "Party" means either SQNM or GSK, and "Parties" means both SQNM and GSK.
      -----                                 -------

17.  "[...***...]" means Genotyping DNA samples [...***...] per Element.
      ---------

18.  "[...***...] Technology" means SQNM's Know-How and Intellectual Property
      ----------------------
     Rights which are necessary to practice [...***...] in combination with
     SQNM's proprietary MassEXTEND(TM) methods and processes claimed under
     SQNM's U.S. Patent No. 6,258,538 and all counterpart foreign equivalent
     patent rights. [...***...] Technology includes, but is not limited to
     experimental procedures, the software that controls the SpectroREADER(TM)
     mass spectrometer for [...***...] and the software that provides
     [...***...].

19.  "Processed SNP Assay" means Assays for putative SNPs that have been
      -------------------
     executed using the MassARRAY(TM) System on the CEPH samples pursuant to the
     detailed Statement of Work in Exhibit A.

20.  "Project" means, collectively, the work, research, deliverables, duties and
      -------
     other obligations which are to be performed and/or provided pursuant to
     this Agreement and which are described in Exhibits A and B as appended
     hereto and hereby incorporated by reference.

21.  "Project Data" shall mean any and all results, data, and information
      ------------
     obtained or resulting from the work performed pursuant to the SOW as set
     forth in Exhibit A, and shall include all the information set forth on
     Exhibit D.

22.  "Project SNPs" means (i) the SQNM-nominated SNPs and (ii) the
       ------------
     GSK-nominated SNPs.

23.  "Reagent" means the oligonucleotide reagents purchased under this Agreement
      -------
     in accordance with Exhibits A and B.

24.  "SNP" shall mean a putative single nucleotide polymorphism as defined by
      ---
     inclusion in the [...***...]

25.  "SNP-Related Information" means the data and information identified in
      -----------------------
     Exhibit D that is necessary (i) for the review and nomination process on
     all Project SNPs, or (ii) to perform the actions necessary to produce and
     perform Processed SNP Assays, Functional Assays, and

                                               *Confidential Treatment Requested

                                        4

<PAGE>

                                  CONFIDENTIAL

     Confirmed SNPs; provided however, that SNP-Related Information shall not
     include Processed SNP Assay Data, as described on Exhibit D.

26.  "SQNM-nominated SNPs" means the existing set of [...***...] SNPs assays
      -------------------
     designated by SQNM to be included in the set of Processed SNPs Assays, all
     of which are [...***...], as of the Effective Date.

27.  "Territory" means worldwide.
      ---------

28.  "Third Party" means any person, party or entity other than GSK and its
      -----------
     Affiliates, or SQNM and its Affiliates, and their respective employees and
     officers. By way of example and not by limitation, Third Parties shall
     include any and all consultants, contractors or other third parties engaged
     by SQNM or GSK or their respective Affiliates pursuant to the terms and
     conditions of this Agreement.

                      ARTICLE II. DELIVERABLES AND PAYMENTS

A.       Statement of Work and Deliverables.

         1.   The obligations of each Party with respect to the work or research
to be performed pursuant to this Agreement and the deliverables as a result of
such work or research are set forth in detail in the Statement of Work for the
Project (the "SOW") which is attached hereto as Exhibit A and hereby
incorporated by reference. As more specifically described in Exhibit A, the
Project will be performed in four phases (hereinafter Phase 1, Phase 2, Phase 3,
and Phase 4), each of which is likely to extend into the other.

         2.   The failure of either party to perform any of its material
obligations pursuant to the SOW shall be deemed a material breach of this
Agreement.

B.       Terms and Conditions of Payments.

         1.   The obligations of each Party with respect to the terms and
conditions of payments to be made pursuant to this Agreement shall be in
accordance with the detailed terms and conditions set forth in this Article II
and in Exhibit B, which is attached hereto and is hereby incorporated by
reference.

         2.   Each Party shall use commercially reasonable efforts to perform
their respective obligations under the SOW. The failure of either party to
perform any of its material obligations with respect to the terms and conditions
of payment shall be deemed a material breach of this Agreement.

C.       SQNM Deliverables to GSK

         1.   On the Effective Date of this Agreement, SQNM will send to GSK in
CD format and via express mail the Project Data set forth in Exhibit D
pertaining to all Confirmed SNPs [...***...] and all Processed SNP Assays
[...***...] from the [...***...] gene-

                                               *Confidential Treatment Requested

                                        5

<PAGE>

                                  CONFIDENTIAL

based SQNM-nominated SNP set. A CD containing all Project Data in existence as
of the Effective Date as outlined in Exhibits A & B will also be sent on the
Effective Date. The Project Data for [...***...] SQNM-nominated SNPs will also
be sent by SQNM and received by GSK as per the Timeline in Exhibit B. A list of
Third Party vendors and information necessary to facilitate negotiations for
Phase 4 Reagent purchases on behalf of both parties will also be sent on the
Effective Date.

     2. SQNM will use reasonable efforts to provide GSK the technical experience
and information needed to facilitate the implementation of the [...***...] at
GSK within [...***...] from the Effective Date. At GSK's request, this shall
include GSK personnel familiarizing themselves with the [...***...] at SQNM's
San Diego facility for a period of time, at GSK's expense.

         3.   A CD of Project Data necessary to review the status of the Project
and for Reagent ordering, or processing and confirmation of the Project SNPs
will be sent to GSK essentially as produced, every [...***...] up to and through
[...***...]. After [...***...], the CD shipment will occur [...***...] for the
remaining duration of this Agreement. SQNM will invoice GSK upon delivery of
each CD shipment of Project Data; provided however, it is understood that,
regardless of the date of invoice, GSK payment dates will be as outlined in this
Agreement.

         4.   During the course of the Project, GSK and SQNM may each desire to
purchase larger quantities of specific oligonucleotides from any of the
approximately [...***...] oligonucleotides that will be designed and tested as
part of this Agreement as part of Phase 4 of the Project. [...***...]

         5.   Invoices for all Phase 4 Reagents co-purchased by SQNM on behalf
of GSK will be paid by GSK either to SQNM or directly to the Third Party vendor
upon receipt of the appropriate amount of the co-purchased Reagent by GSK at its
Research Triangle Park research facility.

         6.   All Project Data and invoices for Processed SNP Assays and Phase 4
Reagent must be received by GSK no later than [...***...], subject to a final
invoice and payment upon termination in accordance with Section D of Article XI.

D.       GSK Deliverables to SQNM

         1.   On or prior to the Effective Date, GSK will send in CD format to
SQNM the information and data required from GSK as outlined in Phase 1 in
Exhibit A for the purpose of facilitating the selection of GSK-nominated SNPs.
This will include public domain SNP data

                                               *Confidential Treatment Requested

                                        6

<PAGE>

                                  CONFIDENTIAL

required of GSK as well as a list of Third Party vendors and information
necessary to facilitate Phase 4 Reagent negotiations on behalf of both parties.

         2.   A total of [...***...] GSK-nominated SNPs will be sent by GSK and
received by SQNM as two groups of [...***...] SNPs each as per the Timeline in
Exhibit B.

         3.   GSK will pay a total of [...***...] for the [...***...] Processed
SNP Assays (to be determined at a rate of [...***...]) which are completed as
part of and according to requirements set forth in Exhibit A and Exhibit B. For
payment by GSK to occur on [...***...], as per subsection (5) below, the Project
Data corresponding to each Processed SNP Assay must be transferred by SQNM to
GSK no later than [...***...] in accordance with the SOW of Exhibit A and
Exhibit B; provided however that GSK shall pay for additional Processed SNP
Assays that are completed prior to the termination date of this Agreement
pursuant to Section D of Article XI. At no time under this Agreement or by
extension of this Agreement in accordance with the Terms for Termination will
GSK pay any cost for an assay where the Project Data is incomplete or the
requirements set forth in the SOW is incomplete for that assay.

         4.   The 1st payment by GSK to SQNM for Processed SNP Assays will be
based on invoices submitted by SQNM on or prior to [...***...] at a rate of
[...***...] completed and will reflect the number of Processed SNP Assays
completed in accordance with the requirements of Exhibits A and B as of
[...***...], and with the Project Data transferred to GSK by that date. However,
it is understood and agreed that payment by GSK for invoice of Processed SNP
Assays received through [...***...]. SQNM will provide documentation of all such
ordered Reagents at [...***...] intervals during this Agreement.

         5.   The second payment by GSK will be based upon invoices submitted by
SQNM on or prior to [...***...] with the payment reflecting the remaining number
of Processed SNP Assays completed in accordance with the requirements of
Exhibits A and B between the [...***...] invoice date and [...***...].
[...***...] in accordance with the SOW of Exhibit A and Exhibit B.

         6.   A final payment shall be made by GSK in accordance with Section D
of Article XI for number of Processed SNP Assays completed in accordance with
the requirements of Exhibits A and B between the [...***...] invoice date and
the termination date. [...***...]

         7.   For any Phase 4 Reagent purchase of [...***...] or greater which
GSK wishes to purchase, GSK will offer in writing and with sufficient detail the
Co-Purchase Option to SQNM.

                                               *Confidential Treatment Requested

                                        7

<PAGE>

                                  CONFIDENTIAL

SQNM will have [...***...] in which to notify GSK in writing whether or not SQNM
will participate in the order and to what extent.

         8.   Invoices for all Phase 4 Reagents co-purchased by GSK on behalf of
SQNM will be paid by SQNM either to GSK or directly to the Third Party vendor
upon receipt of the appropriate amount of the co-purchased Reagent by SQNM at
its La Jolla research facility.

         9.   Invoices submitted by SQNM shall be paid by GSK within
[...***...].

               ARTICLE III. JOINT PLANNING AND STEERING COMMITTEE

A.       Purpose of Joint Planning and Steering Committee.  The Joint Planning
and Steering Committee (JPC) will be responsible for the execution and
monitoring of the Project in accordance with this Agreement. In particular, the
activities of the JPC shall include:

         1.   Facilitate nomination of the [...***...] to be selected by GSK and
processed for the Project from the entire set of candidate SNPs in accordance
with Exhibits A and B.

         2.   Supervision of workflow, including experimental sample transfer,
sample analysis and data quality control, database posting, data analysis and
summary, equipment and software access, training and maintenance.

         3.   Monitor all sample, data, invoice, and payment schedules
throughout the Project in accordance with the timelines listed in Exhibit B.

         4.   Arrange for appropriate price negotiations with mutually agreed
upon Third Party vendors for Phase 4 Reagent orders, and in accordance with
appropriate company procedures of each Party, agree on pricing strategy with
such Third Parties. Coordinate communication of shipment dates, QC information,
and the resulting transfer of Reagent to appropriate Party.

         5.   Coordinate Phase 4 Reagent purchases and transfer and the
Co-Purchase Option.

         6.   Assign tasks and responsibilities taking into account each Party's
respective specific capabilities and expertise in order to enhance efficiency
and synergies.

         7.   Proactively manage collection and transfer of quality data and
consistent and frequent communication with respective management of each Party.

         8.   Ensure overall compliance with the terms of the Agreement
including Exhibits A-D, monetary limits, and legal and intellectual property
related issues.

         9.   Negotiate and resolve issues of performance in accordance with
terms of this Agreement.

B.       JPC Membership.  GSK and SQNM each shall appoint, in their sole
discretion, two or three members to the JPC, which shall include a Co-Chair to
be designated by GSK and a Co-

                                               *Confidential Treatment Requested

                                        8

<PAGE>

                                  CONFIDENTIAL

chair to be designated by SQNM. Substitutes or alternates for the Co-Chairs or
other JPC members may be appointed at any time by notice in writing to the other
Party. The Parties may mutually agree to change the size of the JPC as long as
there shall be an equal number of representatives of each Party on the JPC. The
initial Co-Chairs are [...***...] of GSK and [...***...] of SQNM, with JPC
members of [...***...] and [...***...] of GSK and [...***...] and [...***...] of
SQNM.

C.       JPC Meetings. JPC meetings are to be held at least twice during or
after the term of this Agreement, with one on each respective site, and with one
near the beginning of the Agreement and the last no later than one month post
termination date of this Agreement. The method, location and details of all
other meetings including teleconferences will be determined jointly by the JPC
membership, with special consideration for frequent information transfer each
time data or sample is transferred. Other representatives and participants of a
Party may attend the JPC meeting as needed, but prior notification and approval
must take place. Each JPC meeting will end with a brief summary of issues and
steps taken towards resolution recorded in the minutes.

D.       Quorum: Voting: Decisions.  At each JPC meeting, at least two (2)
member(s) appointed by each Party present in person (or by telephone) shall
constitute a quorum and decisions shall be made by unanimous decision, with each
Party having a single vote.

E.       Dispute Resolution. The resolution of any disputes under this Agreement
shall be handled in the first instance by vote of the JPC Committee. If cannot
be resolved, the dispute shall be escalated to [...***...] of GSK and
[...***...] of SQNM, who together shall try to resolve the dispute for a period
of thirty (30) days. If the dispute cannot be resolved after a thirty (30) day
period, each Party shall be free to pursue all available administrative and/or
judicial remedies or actions.

F.       JPC Survival. The JPC shall survive any expiration or termination of
this Agreement (other than for breach) for a period of one (1) year from the
date of such expiration or termination, which shall be extendable by the mutual
written agreement of the Parties, in order to manage any affairs that may occur
after such expiration or termination, such as review of any publication
permitted under this Agreement.

              ARTICLE IV. INTELLECTUAL PROPERTY RIGHTS AND LICENSES

A.       Ownership and Licenses to New IP; Use of  Project SNPs and Reagents

         1.   The ownership of all New IP arising from the work performed under
this Agreement shall be determined in accordance with U.S. patent law (ownership
is determined by inventorship) in the case of patent rights, and in accordance
with the appropriate federal or state law in the case of all other Intellectual
Property Rights arising from New IP.

2.       GSK and its Affiliates shall have [...***...] to use all New IP arising
from the Project for GSK's [...***...] only under any and all
Intellectual Property Rights which SQNM might have or acquire in and to such New
IP and in and to any and all U.S. patents, patent applications and foreign
equivalents and counterparts thereof disclosing such New IP. This

                                               *Confidential Treatment Requested

                                        9

<PAGE>

                                  CONFIDENTIAL

license shall not be sublicenseable or transferable to Third Parties;
[...***...] and provided further [...***...]. Also for the avoidance of doubt,
there shall be no restriction or obligation upon GSK to use any of such New IP
[...***...]. The license pursuant to this Section shall not extend to SQNM's
Background Technology (for example but not limited to SQNM's instrumentation,
MassARRAY(TM), MassEXTEND(TM) and [...***...] Technology) or to any
improvements, modifications, or enhancements to SQNM's Background Technology.

         3.   SQNM and its Affiliates shall have [...***...] to use all New IP
arising from the Project for SQNM [...***...] only under any and
all Intellectual Property Rights which GSK might have or acquire in and to such
New IP and in and to any and all U.S. patents, patent applications and foreign
equivalents and counterparts thereof disclosing such New IP. This license shall
not be sublicenseable or transferable to Third Parties; [...***...] and provided
further [...***...].

         4.   The Parties agree that all Project SNPs are in the public domain.
Therefore each Party agrees that it shall not in any manner during the term of
this Agreement and forever thereafter, directly or indirectly, prohibit,
restrict or otherwise substantially inhibit the other Party from making any use
whatsoever of any or all of the Project SNPs and any and all information related
thereto which is in the public domain. However, except for the licenses
expressly granted herein with respect to New IP, nothing herein shall be
construed as granting to either Party a license under any of the Intellectual
Property Rights of the other Party which may arise as a result of any
technology, inventions and/or discoveries, which are based upon or derived from
one or more of the Project SNPs. For the avoidance of doubt, nothing in this
Section provides either Party, or should be construed to provide either Party,
expressly or by implication, with any right or license to use any of the other
Party's Background Technology. Also for the avoidance of doubt, nothing in this
Agreement shall be construed or interpreted in any way as a restriction or
limitation upon GSK or its Affiliates of its right to develop, either alone or
by using Third Parties, assays for any one or more SNPs which are derived from
[...***...], regardless of whether such SNPs represent a subset or all of the
Project SNPs hereunder, without any obligation to SQNM.

         5.   GSK shall be the sole owner of any and all Reagents that it
purchases as a part of Phase 4, subject to the following. The Parties agree that
GSK and its Affiliates shall be free to use such Reagents during the term of
this Agreement and forever thereafter, for GSK's Internal Research Purposes;
provided, however, that such right shall not be construed to, and does not,

                                               *Confidential Treatment Requested

                                       10

<PAGE>

                                  CONFIDENTIAL

expressly or impliedly, provide GSK with a license under any SQNM Background
Technology or Intellectual Property Rights thereto. For the avoidance of doubt,
GSK's Internal Research Purposes shall include [...***...]. Also for the
avoidance of doubt, there shall be no restriction or obligation upon GSK to use
any of such Reagents [...***...].

B.       Ownership of Background Technology and Background Data

         1.   All Background Technology and all Background Data shall be and
remain the sole property of the Party which owns such Background Technology and
such Background Data as of the Effective Date.

         2.   Each Party agrees to treat as Confidential Information, the
Background Technology and the Background Data provided from one party to the
other hereunder which is not already in the public domain.

C.       Licenses to SQNM Background Technology; Options to such Licenses

          1. GSK shall have the option, at its sole discretion, to purchase from
SQNM upon commercially reasonable terms to be negotiated by the Parties in good
faith, the items listed in Exhibit C1 under MassARRAY(TM) System components
(Robolab, SpectroPOINT(TM) dispenser, SpectroREADER(TM) mass spectrometer,
SpectroTYPER(TM) software, SpectroDESIGNER(TM) software and 384 SpectroCHIP(TM)
DNA Analysis chips) as follows. Included within the prices for the products
shown in Exhibit C1 shall be any and all required fees for a non-exclusive,
non-transferable, non-sublicenseable, license to GSK for GSK Internal Research
Purposes under SQNM's Intellectual Property Rights in those products and
including SQNM's Know-How related to the use of such products. With the purchase
of SQNM's 384 SpectroCHIP(TM) DNA Analysis chips (hereinafter the "Chips"), SQNM
shall grant GSK a non-exclusive, limited right to use, without the right to
transfer, sublicense or otherwise permit Third Parties to use, the Chips, in
conjunction with the MassARRAY(TM) System, for GSK's Internal Research Purposes,
within the Territory, for performing SQNM's proprietary MassEXTEND(TM) methods
and processes claimed under the `538 Patent (as defined in Background
Technology) and all counterpart foreign equivalent patent rights. The pricing of
SQNM's Chips set forth in Exhibit C1 includes a fully prepaid license fee in
consideration for this limited grant; such right granted being limited to the
number of Elements per Chip purchased (i.e., three hundred eighty four (384)),
and such right granted being limited to use by GSK for GSK Internal Research
Purposes, in the Territory. This license [...***...] to Third Parties. This
option shall be for a period of [...***...] from the Effective Date of this
Agreement. In the event that GSK chooses to exercise this option, GSK shall have
the [...***...] to purchase such products on commercially reasonable terms to be
negotiated by the Parties in good faith. [...***...], the terms of any such
agreement including any necessary licenses shall be at a cost no greater than
and on terms no less favorable to GSK than those set

                                               *Confidential Treatment Requested

                                       11

<PAGE>

                                  CONFIDENTIAL

forth in Exhibit C1 attached hereto. However, the prices provided in Exhibit C1
are subject to change at the sole discretion of SQNM after [...***...].
Notwithstanding the above, nothing in this Agreement shall be construed or
interpreted in any manner as an obligation upon GSK to enter into such a
purchase pursuant to this Section, or as an acceptance by GSK of any part or all
of the terms set forth in Exhibit C1.

         2. GSK shall have the option, at its sole discretion, to acquire upon
commercially reasonable terms to be negotiated by the Parties in good faith, a
non-exclusive non-transferable, non-sublicenseable, license to use SQNM's
[...***...] Technology (referred to as MassEXTEND(TM) [...***...] in Exhibit C2)
for GSK [...***...] under SQNM's Intellectual Property Rights as follows. In the
event that GSK chooses to exercise this option, GSK shall have the irrevocable
right to acquire from SQNM on commercially reasonable terms to be negotiated by
the parties in good faith any and all non-exclusive licenses under SQNM
Intellectual Property Rights necessary for GSK's [...***...] that include
Genotyping [...***...] DNA samples [...***...] ("[...***...]"). SQNM will, under
such a license, grant to GSK a non-exclusive, limited right to use, without the
right to transfer, sublicense or otherwise permit Third Parties to use the
Chips, in conjunction with the MassARRAY(TM) System, in the Territory, for
[...***...] with SQNM's proprietary MassEXTEND(TM) methods and processes claimed
under the `538 Patent (as defined in Background Technology) and all counterpart
foreign equivalent patent rights, in consideration for GSK's payment of the
additional license fee to SQNM which is identified in Exhibit C2. However, for a
period of [...***...] from the Effective Date of this Agreement, any such
license entered into pursuant to the option under this Section shall not extend
to the use of SQNM's [...***...] Technology for the measurement of [...***...].
Such excluded use shall, at the expiration of said [...***...], be thereafter
included within any such license obtained by GSK pursuant to the option under
this Section. This option shall be for a period of [...***...] from the
Effective Date. Until [...***...], the terms of any such license shall be at a
cost no greater than and on terms no less favorable to GSK than those set forth
in Exhibit C2 attached hereto. However, the license fees provided in Exhibit C2
are subject to change at the sole discretion of SQNM after [...***...]. This
license shall not be sublicenseable or transferable to Third Parties.
Notwithstanding the above, nothing in this Agreement shall be construed or
interpreted in any manner as an obligation upon GSK to enter into such a license
pursuant to this Section, or as an acceptance by GSK of any part or all of the
terms set forth in Exhibit C2.

                ARTICLE V. CONFIDENTIAL INFORMATION AND MATERIALS

A.       During the term of this Agreement, one Party may provide to the other
proprietary and confidential information and/or materials that the providing
Party considers essential for the purpose of this Agreement. Such proprietary
and confidential information and/or materials shall include, but is not limited
to, any and all Background Data and Background Technology, Project Data as well
as business strategy and financial information, owned or provided by one Party
(the providing Party) to the other Party (the receiving Party) hereunder. The
providing Party shall mark or designate in writing such information and/or
materials (including electronic forms thereof) as confidential and proprietary
of the providing Party. With respect to any confidential and proprietary
information which are disclosed orally from one party to the other, such
information shall not be subject to the confidentiality and non-use provisions
of this Article

                                               *Confidential Treatment Requested

                                       12

<PAGE>

                                  CONFIDENTIAL

unless a written summary of the orally disclosed information is provided to the
receiving party by the providing party within thirty (30) days of the date of
the initial disclosure of such information. The terms and provisions of this
Article V with respect to confidentiality and non use of proprietary and
confidential information of the Parties shall supersede any and all prior
confidentiality agreements between SQNM and GSK, or between any Third Party and
SQNM or its Affiliates, or any Third Party and GSK or its Affiliates with
respect to the subject matter of this Agreement.

B.       In the event a Party receives such proprietary and confidential
information and/or materials of the other Party, unless otherwise provided in a
separate agreement between the Parties, the receiving Party shall use it only to
the extent needed to perform its obligations under this Agreement or to exercise
its rights and licenses to the extent permitted by this Agreement. The receiving
Party further agrees that during the Term of this Agreement and for a period of
seven (7) years from such disclosure, such Party will not disclose or permit or
cause to be disclosed, directly or indirectly, such proprietary and confidential
information and/or materials received from the disclosing Party to any Third
Party, or use it for any other purpose, without the prior written consent of the
disclosing Party, except to the extent necessary to perform its obligations or
exercise its rights and licenses under this Agreement. In addition, in handling
proprietary and confidential information and/or materials of the other Party,
whether to perform such obligations or to exercise such rights and licenses, the
receiving Party shall use the same degree of care that it uses to protect its
own confidential information and/or materials of similar value, but in no event
less than the ordinary degree of care required by law to preserve the secrecy of
information that under such law is deemed confidential. By way of example, such
efforts will include the act of obtaining the execution of appropriate
confidentiality agreement from those of its agents, contractors, consultants,
customers, subcontractors, or other Third Parties to whom such information is
disclosed, subject always to the provisions of this Agreement with respect to
Third Parties. Notwithstanding the foregoing, each Party may include
confidential information, to the limited extent necessary, in legal documents,
including patent applications, needed for securing intellectual property rights
in any New IP.

C.       As used herein, proprietary and confidential information shall not
include information that the receiving Party can demonstrate by competent
written evidence: (i) is in the public domain or becomes part of the public
domain through no act or omission of the receiving Party; (ii) was already known
to the receiving Party at the time it received such information; (iii) is or was
developed independently by the receiving Party without reference to the
proprietary and confidential information of the other Party; or (iv) is required
to be disclosed by law or by regulation or by a competent court order, provided
that prior to such disclosure the receiving Party has promptly notified the
disclosing Party of such required disclosure and has provided the disclosing
party with an adequate and timely opportunity to object to such requirement, or
to limit the scope of such disclosure or to obtain confidential treatment
thereof. The occurrence of either (i) or (ii) or (iii) or (iv) above shall not
be construed as granting any rights, express or implied, under any patents or
other intellectual property rights of the disclosing Party that cover
information meeting one or more of these exceptions.

D.       In the event of any termination or expiration of this Agreement
hereunder, each receiving Party agrees that it and any Third Party to whom it
provided confidential or proprietary

                                       13

<PAGE>

                                  CONFIDENTIAL

information and/or materials of the disclosing Party shall, as directed by the
disclosing Party, promptly return or destroy and certify in writing the
destruction of all originals, copies, versions and modifications, in whatever
form, format or media existing, of the proprietary and confidential information
and/or materials disclosed to it by the disclosing Party, without retaining any
copy thereof, except that one copy of such proprietary and confidential
information and/or materials may be retained in the confidential legal files of
the receiving Party solely for the purpose of assuring compliance with its
obligations under this Agreement or for the purpose of defending or maintaining
any litigation (including any administrative proceeding) relating to this
Agreement.

                             ARTICLE VI. PUBLICATION

A.       Conditions of Publication. Publication by either Party of any of the
Project Data, New IP or other information or data arising from the Project
requires the prior express written approval and review by the other Party for
publication of any kind of any of such data, results or information arising from
the Project, which approval shall not be unreasonably withheld. The sole
exception to this shall be the right of SQNM to publicly post any or all of the
[...***...], indicating that MassARRAY(TM) assays have been designed and are
available through SQNM as part of their commercial business. In such a posting
by SQNM, [...***...] at any given time. In addition, no Project Data may be
publicly posted, except as already in the public domain and except that any
SNP-Related Information as set forth in Exhibit D may be posted by SQNM after
[...***...] from the termination or expiration date of this Agreement. For the
avoidance of doubt, any posting which is encompassed within Section VI. C. shall
not be subject to the restrictions set forth in this Section VI. A.

B.       [...***...] are Confidential Information. SQNM agrees that any
information which might in any way indicate that [...***...] is to be treated as
GSK's Confidential Information and SQNM's use of such information is subject to
the provisions of Article V, and that, notwithstanding anything to the contrary
contained herein, during the term of this Agreement and thereafter, SQNM shall
not disclose or permit to be disclosed to any Third Party any of such
information. GSK agrees that it will provide SQNM with [...***...] that GSK
agrees may be provided by SQNM to, for example, [...***...].

C.       SQNM Commercial Rights. It is understood and agreed that SQNM shall
have the right to sell and otherwise commercialize [...***...] developed and
owned by it hereunder as part of its commercial business, subject to the terms
and conditions of this Agreement, including without limitation, the restrictions
and limitations set forth in Article IV, V, VI and VIII.

                ARTICLE VII. SUBCONTRACTING WORK TO A THIRD PARTY

A.       Use of GSK-Approved Third Parties Only.  SQNM shall not delegate,
subcontract or assign any of its rights and/or obligations hereunder or any of
the work to be performed by it under the Statement of Work to any Third Party
without obtaining the prior written consent of

                                               *Confidential Treatment Requested

                                       14

<PAGE>

                                  CONFIDENTIAL

GSK, which consent shall not be unreasonably withheld. In the event that SQNM
wishes to engage a Third Party such as a contractor, agent, consultant or other
Third Party to perform any part of its obligations under the Statement of Work,
SQNM, shall notify GSK in writing, including by email or otherwise, of the
identity, address, and proposed role of the Third Party sought to be hired. The
hiring of said Third Party shall be subject to the prior written approval of
GSK. In the event that GSK approves the hiring of the Third Party, SQNM shall
ensure that the Third Party executes an agreement with SQNM, said agreement
having provisions governing the assignment of Intellectual Property Rights, and
the maintenance in confidence and non-use of proprietary information and other
confidential information on terms conforming to all of the provisions of this
Agreement. The individual, in performing the work under this Agreement, will not
be acting as an employee or agent of either SQNM, nor will the individual be
entitled to any of the entitlements or benefits which normally accrue to SQNM
employees. Notwithstanding anything to the contrary herein, despite engaging a
Third Party to perform its obligations hereunder, SQNM shall remain liable for
the performance of such obligations in accordance with the terms hereof.

          B. GSK's use of Processed SNP Assays [...***...] for [...***...]. For
period of [...***...] from the date of expiration or termination of this
Agreement, GSK shall have an obligation to [...***...]. SQNM will within ten
(10) business days of such written notification either [...***...] or will
provide GSK [...***...]. [...***...] If GSK, using reasonable and
industry-accepted commercial considerations, [...***...].

                  ARTICLE VIII. REPRESENTATIONS AND WARRANTIES

A.       Each Party hereby represents and warrants that, to the best of its
knowledge, all of the Project SNPs that it nominates for use in the Project are
public domain SNPs and are present in the [...***...].

B.       Each Party hereby represents and warrants that, to the best of its
knowledge at the Effective Date, it has not granted to any Third Party or
government entity any exclusive license or other encumbrance upon the rights of
the other Party to use any of the Project SNPs or SNP-Related Information as set
forth herein.

C.       SQNM hereby represents and warrants that it has the right to convey to
GSK the licenses, options and rights granted hereunder, and each Party hereby
represents and warrants that the performance of all of its obligations pursuant
to this Agreement does not conflict with any of its obligations pursuant to the
provisions of any other agreement in effect between it and any Third Party or
government entity.

D.       SQNM hereby represents and warrants that, to the best of its knowledge,
the licenses to which GSK has options to acquire hereunder, if entered into,
would grant GSK and its Affiliates

                                               *Confidential Treatment Requested

                                       15

<PAGE>

                                  CONFIDENTIAL

the right and ability under SQNM's Intellectual Property Rights to practice
SQNM's MassEXTEND(TM) and [...***...] Technology with the Functional Assays
developed hereunder for any and all of GSK's Internal Research Purposes, and
that no additional licenses from SQNM under any other SQNM Intellectual Property
Rights would be required.

E.       SQNM hereby represents and warrants that it shall not, [...***...].
For the avoidance of doubt, with respect to this section VIII. E., [...***...].

                       ARTICLE IX. DISCLAIMER OF LIABILITY

A.       Except as expressly stated in this Agreement, neither Party shall have
any liability whatsoever arising from any action or omission of the other Party
in the performance or failure of the other Party to perform its obligations
pursuant to this Agreement and/or the SOW hereunder. Furthermore, except as
expressly stated in this Agreement, neither Party shall have any liability
whatsoever arising from any activities of the other Party with respect to the
use, handling, storage or disposal by one Party of any materials provided to it
by the other Party pursuant to this Agreement.

B.       NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT,
SPECIAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, TORT OR OTHERWISE,
INCLUDING, WITHOUT LIMITATION, ANY LOST DATA, LOST REVENUE OR LOST PROFITS, EVEN
IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF OR COULD HAVE FORESEEN
SUCH DAMAGES.

                              ARTICLE X. INDEMNITY

A.       SQNM shall indemnify and hold harmless GSK and its Affiliates with
respect to any and all claims, suits, causes of action, damages and costs
(including reasonable attorney's fees) asserted by any Third Party against SQNM
and/or GSK and arising from any of SQNM's actions or omissions under this
Agreement, except to the extent that such claims, suits, causes of actions,
damages and costs are due to the gross negligence or willful misconduct of GSK.

B.       GSK shall indemnify and hold harmless SQNM and its Affiliates with
respect to any and all claims, suits, causes of action, damages and costs
(including reasonable attorney's fees) asserted by any Third Party against GSK
and/or SQNM and arising from any of GSK's actions or omissions under this
Agreement, except to the extent that such claims, suits, causes of actions,
damages and costs are due to the gross negligence or willful misconduct of SQNM.

C.       SQNM shall indemnify and hold harmless GSK and its Affiliates with
respect to any and all claims, suits, causes of action, damages and costs
(including reasonable attorney's fees)

                                               *Confidential Treatment Requested

                                       16

<PAGE>

                                  CONFIDENTIAL

asserted by any Third Party against GSK and/or SQNM alleging infringement of the
intellectual property rights of any Third Party based upon GSK's use of the SQNM
products identified in Exhibits C1 or C2 in accordance with the product
specifications and information supplied by SQNM to GSK regarding their use, or
any use by GSK of MassEXTEND(TM) methods or any of SQNM's Background Technology
or Data pursuant to the terms or conditions of any license entered into between
GSK and SQNM for such Background Technology or Data as a result of this
Agreement. However, SQNM's indemnification shall apply only with respect to the
specific products and processes encompassed by SQNM's Background Technology or
Data and not to, for example, and not limited to, any Third Party intellectual
property rights in any underlying genetic information or general methods of
genetic analysis or sample preparation. SQNM's liability under this Section C
for the infringement of any such Third Party intellectual property rights shall
in no event be greater than two (2) times the amount of any direct monetary
consideration actually received by it under this Agreement, including any
amounts received in consideration for the sale of the products or licenses
identified on Exhibits C1 or C2.

D.       GSK shall indemnify and hold harmless SQNM and its Affiliates with
respect to any and all claims, suits, causes of action, damages and costs
(including reasonable attorney's fees) asserted by any Third Party against SQNM
and/or GSK for any illness, injury or other damage resulting from GSK or its
Affiliates' use of the Project Data or New IP developed hereunder, or GSK's use
under this Agreement of SQNM's Background Technology or Data, except to the
extent that any such claims, suits, causes of action, damages and costs are due
to the gross negligence or willful misconduct of SQNM.

E.       SQNM shall indemnify and hold harmless GSK and its Affiliates with
respect to any and all claims, suits, causes of action, damages and costs
(including reasonable attorney's fees) asserted by any Third Party against GSK
and/or SQNM for any illness, injury or other damage resulting from SQNM or its
Affiliates' use of the Project Data or New IP developed hereunder, except to the
extent that any such claims, suits, causes of action, damages and costs are due
to the gross negligence or willful misconduct of GSK.

                        ARTICLE XI. TERM AND TERMINATION

A.       The term of this Agreement shall run from the Effective Date (date
signed by both parties) until [...***...] and the Project shall automatically
expire if not completed by the same date. GSK shall have the sole option to
extend the term of this Agreement until [...***...] or until the last of the
Project Data is received by GSK at its site, whichever is earlier.

B.       Either Party may terminate the Agreement for cause to be effective
immediately upon receipt of written notice to the other Party in the event that
the other Party is in material breach because:

         1.   GSK is more than 30 days late on any payment due hereunder, or

         2.   SQNM has failed to physically deliver to GSK by [...***...] the
Project Data for [...***...] Processed SNP Assays with a corresponding
[...***...] Functional Assays.

                                               *Confidential Treatment Requested

                                       17

<PAGE>

                                  CONFIDENTIAL

C.       Either Party may terminate this Agreement for cause due to a material
breach of this Agreement by the other Party, other than as set forth in B above,
such termination to be effective upon the expiration of thirty (30) days from
the date that written notice is first received by the other Party setting forth
the details of any such alleged breach, if the other Party has failed to cure
such breach within said 30 day period.

D.       A summary accounting and invoice for all Processed SNP Assays completed
by the termination date in accordance with Exhibits A and B and the
corresponding Project Data delivered to GSK as well as any outstanding Phase 4
Reagents purchased by either Party under the Co-Purchase Option will be issued
on the termination date and be paid by each Party within thirty (30) days
following the termination date. SQNM agrees that upon any notice of termination
provided to it by GSK, that SQNM will immediately cease the creation of any
further Project Data and Reagent orders.

                           ARTICLE XII. MISCELLANEOUS

A.       No Agency. Both Parties shall, at all times during the performance of
this Agreement, remain as independent contractors, and nothing in this Agreement
shall be construed or interpreted to make the Parties partners, joint venturers
or agents of one another for any purpose whatsoever. Neither Party is
authorized, in the name of or on behalf of the other, to transact any business,
incur any obligation, undertake any activities, or otherwise to bind the other
in any manner whatsoever.

B.       Insurance.  Each Party shall carry and maintain in full force insurance
required by applicable law and any other insurance customary in its field of
work.

C.       Publicity. Each Party agrees that it will not disclose the terms of
this Agreement or use the other Party's name in any advertising, promotional
materials, or publicity without the prior written approval of the other Party,
which consent shall not be unreasonably withheld. The terms of this Agreement
shall be deemed Confidential Information under this Agreement, except that the
Parties shall mutually agree upon a press release to be released promptly after
the signing of this Agreement. SQNM understands and agrees that the terms set
forth in this Agreement disclose highly proprietary business strategies of GSK
which, if disclosed publicly, would significantly injure GSK's competitive
position with respect to the subject matter of this Agreement. Accordingly, in
the event SQNM is required to publicly disclose the terms of this Agreement
pursuant to the rules of any securities exchange or the U.S. Securities and
Exchange Commission, SQNM shall redact as much Confidential Information as is
permitted under such rules and shall coordinate all such redactions with GSK.

D.       Notices. Unless otherwise set forth in this Agreement, all notices
necessary or desirable to be given hereunder shall be in writing and shall be
deemed given (i) three (3) days after having been sent by registered or
certified mail, return receipt requested, postage prepaid; or (ii) one (1) day
after deposit with a commercial overnight carrier with written verification of
receipt; or (iii) one (1) day after transmission by facsimile. All
communications will be sent to the addresses set forth below or to such other
address as may be designated by a party by giving written notice to the other
Party pursuant to this Paragraph:

                                       18

<PAGE>

                                  CONFIDENTIAL

SQNM:    For technical matters:

                           Name:            [...***...]
                           Address:         3595 John Hopkins Ct.
                                            San Diego, CA 92121
                           Telephone:       (858) 202-9000
                           Fax:             (858) 202-9127
                           Email:           [...***...]@sequenom.com

SQNM:    For matters related to contract administration:

                           Name:            [...***...]
                                            [...***...]
                           Address:         3595 John Hopkins Ct.
                                            San Diego, CA 92121
                           Telephone:       (858) 202-9000
                           Fax:             [...***...]
                           Email:           [...***...]@sequenom.com

GSK:     For technical matters:

                           Name:            [...***...]
                                            [...***...]
                           Address:         GlaxoSmithKline
                                            5 Moore Drive
                                            Research Triangle Park, NC 27709
                           Telephone:       [...***...]
                           Fax:             [...***...]

GSK:     For matters related to contract administration:

                           Attention:       General Counsel
                           Address:         GlaxoSmithKline
                                            One Franklin Plaza
                                            P.O. Box 7929
                                            Philadelphia, PA 19101
                           Fax:             [...***...]

E.       Compliance with Law; Governing Law; Dispute Resolution.

         1.   Each Party hereby represents that it and its Affiliates and
approved Third Parties hired pursuant to Article VII hereunder shall perform all
of its duties and obligations under this Agreement and shall use, store, handle
and dispose of any and all materials received from the other Party in compliance
with all applicable federal, state and local laws and regulations, including but
not limited to all applicable laws and regulations related to informed patient
consent and privacy.

                                               *Confidential Treatment Requested

                                       19

<PAGE>

                                  CONFIDENTIAL

         2.   This Agreement shall be construed and interpreted under and any
controversy hereunder shall be determined in accordance with the laws of the
State of California, without reference to its conflict of law rules. The Parties
agree that in the event that any controversy, claim or dispute between the
Parties arising out of or relating in any way to this Agreement cannot be
resolved by the Parties by mutual negotiation through the JPC and after
escalation to Senior Management pursuant to Article III hereunder, then both
Parties shall be free to pursue any and all available and proper administrative
and judicial remedies and causes of action available at law and in equity.

F.       Successors and Assigns: This Agreement shall be binding upon the
successors and assigns of the Parties, and the name of a Party appearing herein
shall be deemed to include the names of its successors and assigns; provided
always that nothing herein shall permit any assignment by either Party except as
expressly provided herein.

G.       Assignment:  Neither Party may assign this Agreement or its rights and
obligations hereunder, in whole or in part, to any Third Party without the prior
written consent of the other Party; provided, however, that either Party may
assign this Agreement or its rights and obligations hereunder, in whole or in
part, to one or more of its Affiliates, or to any entity with which it may merge
or consolidate, or to which it may sell or transfer all or substantially all of
its assets to which this Agreement relates, without obtaining the consent of the
other Party.

H.       Force Majeure: Neither Party will be liable to the other or deemed in
default hereunder for any failure to perform or delay in performing due to
causes beyond its reasonable control, including, without limitation, fire,
flood, accident, strike, riot, civil commotion, act of God, or war or other
hostilities. Each Party must use its best efforts to avoid any such failure or
delay and must resume performance under this Agreement as promptly as possible
after any such failure or delay. If either Party becomes aware of any such
factor that would cause a delay or failure in performance, it must immediately
notify the other Party in writing of the existence of such factor and probable
length of continuation thereof.

I.       Entire Agreement-Modification: This Agreement, together with Exhibits
A-D appended hereto and hereby incorporated by reference, contain the entire
understanding and agreement of the Parties hereto with respect to the matters
herein contained. Neither Party hereto shall be bound by any oral or other
agreement or understanding which is not expressly contained herein. This
Agreement may be modified only by means of a written document signed by the duly
authorized representatives of each of the Parties hereto.

J.       No  Waiver:  Failure  on either  Party's  part to  exercise  any rights
or privileges granted to it or to insist upon full performance of all
obligations or duties assumed by the other Party shall not be construed as
waiving any such rights, privileges, obligations or duties or creating any
custom contrary thereto.

K.       Survival:  The provisions of Articles II.B.1, II. C. 5-6, II.D.3-6,
II.D. 8-9, III.F, IV, V, VI, VII.B, VIII, IX, X, XI.D and XII shall survive any
expiration or termination of this Agreement according to their respective terms
and conditions.

                                       20

<PAGE>

                                  CONFIDENTIAL

L.       Severability:  If any provision of this  Agreement is found to be
invalid, illegal or unenforceable by a court of competent jurisdiction, the
validity, legality and enforceability of the remaining provisions shall in no
way be affected or impaired thereby.

M.       Counterparts:  This  Agreement  may be executed in any number of
counterparts, each of which shall be deemed an original but all of which shall
constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be signed by their
thereunto duly authorized representatives as of the date first written above.

SEQUENOM, INC.

/s/ Antonius Schuh
----------------------------

By:  Antonius Schuh
   -------------------------

Title: President and Chief Executive Officer
      --------------------------------------

SMITHKLINE BEECHAM CORPORATION         GLAXO GROUP LIMITED

/s/ Donald F. Parman                   /s/  Donald F. Parman
----------------------------           -----------------------------

By:  Donald F. Parman                  By: Donald F. Parman
    ------------------------               -------------------------

Title: Vice President and Secretary    Title:  Attorney-in-Fact
       ----------------------------           ----------------------

                                       21

<PAGE>

                                  CONFIDENTIAL

                                   APPENDICES

                                    EXHIBIT A

                     Statement Of Work (SOW) for the Project

PROJECT SUMMARY

GlaxoSmithKline (GSK) and Sequenom (SQNM) will equally and individually elect
[...***...], respectively, to be processed in the Project. Oligonucleotide
primer set reagents to assay each SNP using SQNM's MassARRAY(TM) System will be
designed, ordered, and used in assays during the course of this Project. The
assays will be tested on [...***...] human [...***...] DNAs, to generate
[...***...], of which, it is anticipated that a minimum of [...***...].

[...***...]

4.       Receiving Inspection Criteria

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------
              RECEIVING INSPECTION CRITERIA                  PASS     FAIL                       COMMENTS
------------------------------------------------------------------------------------------------------------------------------
<S>           <C>                                            <C>      <C>       <C>

Plate Name

------------------------------------------------------------------------------------------------------------------------------

Vendor Reference/Order Number

------------------------------------------------------------------------------------------------------------------------------

Verify plate name is correct.

------------------------------------------------------------------------------------------------------------------------------

Verify labeled concentration is correct.

------------------------------------------------------------------------------------------------------------------------------

Verify correct volume.

------------------------------------------------------------------------------------------------------------------------------

Vendor Certificate of Analysis                                Supplied
(documentation supporting Supplier's testing)
                                                              Not Supplied      State reason:

------------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                               *Confidential Treatment Requested

                                       A-1

<PAGE>

                                  CONFIDENTIAL

5.       Additional Check for Supplier Qualification (if applicable)

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------
              RECEIVING INSPECTION CRITERIA                  PASS     FAIL                       COMMENTS
------------------------------------------------------------------------------------------------------------------------------
<S>           <C>                                            <C>      <C>       <C>

Concentration [...***...]

------------------------------------------------------------------------------------------------------------------------------

EXTEND Spectrum

------------------------------------------------------------------------------------------------------------------------------
</TABLE>

Disposition:    Accept   Reject  NCMR #
                                        --------------------------

QC Receiving Inspector

Sign/Date:
           ---------------------------------------------------------------------

Sequence Format Specifications Document, Sept 8 2001, Doc. No 4005.001.R01

[...***...]

                                               *Confidential Treatment Requested

                                       A-2

<PAGE>

                                  CONFIDENTIAL

                                    EXHIBIT B

                                    Timelines

 [...***...]

                                               *Confidential Treatment Requested

                                       B-1

<PAGE>

                                  CONFIDENTIAL

                                   EXHIBIT C1

                               Quote For Equipment

[...***...]

Project 2 - MassARRAY(TM) Equipment Purchase Summary

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------------------
                    MassARRAY(TM) System Components                      Units         Per Unit Pricing      Total Price
---------------------------------------------------------------------------------------------------------------------------
<S>                                                                    <C>                <C>                <C>

Robolab(TM) - Automated Base Extension High Throughput System           [...***...]        [...***...]         [...***...]
---------------------------------------------------------------------------------------------------------------------------

SpectroPOINT(TM) - Nanoliter transfer device for sample spotting on     [...***...]        [...***...]         [...***...]
SpectroCHIPs(TM)
---------------------------------------------------------------------------------------------------------------------------

SpectroREADER(TM) - Mass Spectrometer                                   [...***...]        [...***...]         [...***...]
---------------------------------------------------------------------------------------------------------------------------

SpectroTYPER(TM)RT - Real-time data analysis workstation               [...***...]        [...***...]         [...***...]
---------------------------------------------------------------------------------------------------------------------------

SpectroDESIGNER(TM) - Assay design software, capable of multiplex       [...***...]        [...***...]         [...***...]
assay design
---------------------------------------------------------------------------------------------------------------------------
</TABLE>
*[...***...] for the first 12 months after installation of the
MassARRAY(TM) system at a GSK facility with GSK's investment in the Project

Selected MassARRAY Consumables

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------------------
Item                                                                                 Catalog Number         Price
---------------------------------------------------------------------------------------------------------------------------
<S>                                                                                  <C>                  <C>
384 SpectroCHIP(TM) DNA Analysis chip pack - (includes ten 384 Element chips)              00601           [...***...]
---------------------------------------------------------------------------------------------------------------------------
</TABLE>

                         PATENTS AND PATENT APPLICATIONS
                           UNDER BACKGROUND TECHNOLOGY

United States Patent No. 6,258,538 (S.N. 09/287,679)

[...***...]

                                               *Confidential Treatment Requested

                                      C1-1

<PAGE>

                                  CONFIDENTIAL

                                   EXHIBIT C2

                    Quote For MassEXTEND(TM) [...***...] LICENSE

[...***...]

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------
               MassEXTEND(TM) [...***...] License Fees              Units       Per Unit Pricing     Total Price
------------------------------------------------------------------------------------------------------------
<S>                                                          <C>            <C>                  <C>
   Internal Research license enabling [...***...]**

  -   First Year Access Fee                                  [...***...]       [...***...]       [...***...]

  -   License for subsequent years                           [...***...]       [...***...]       [...***...]
------------------------------------------------------------------------------------------------------------
</TABLE>
** The License and License fees for MassEXTEND(TM) [...***...] are [...***...].

                         PATENTS AND PATENT APPLICATIONS
                           UNDER BACKGROUND TECHNOLOGY

United States Patent No. 6,258,538 (S.N. 09/287,679)

[...***...]

                                               *Confidential Treatment Requested

                                      C2-1

<PAGE>

                                  CONFIDENTIAL

                                    EXHIBIT D

                                  Project Data

[...***...]

* Confidential Treatment Requested

                                       D-1<PAGE>

                                                                 EXHIBIT 10.99.1

                              CONSULTING AGREEMENT
                              --------------------

           THIS CONSULTING AGREEMENT is made and effective as of the ninth day
of October, 2001, by and between GABRIEL ZEITOUNI ("Zeitouni") and TARRANT
APPAREL GROUP, a California corporation (the "Company"), with respect to the
following facts:

           A.     Pursuant to that certain Employment Agreement dated as of May
27, 1994, between Zeitouni and the Company, as amended (the "Employment
Agreement"), the Company has employed Zeitouni.

           B.     Pursuant to that certain Stock Repurchase Agreement dated as
of July 10, 2000, between Zeitouni and the Company, as amended (the "Option
Agreement"), Zeitouni has the right (the "Put Option") to require the Company to
purchase from Zeitouni up to 80,890 shares of the Common Stock of the Company at
$18.54 per share.

           C.     Zeitouni is indebted to the Company for amounts advanced to
him, in the aggregate amount of $738,500.00.

           D.     The parties each desire, among other things, to terminate the
employment of Zeitouni by the Company, provide for Zeitouni to render certain
consulting services to the Company, amend the Put Option and make certain
provisions regarding the repayment of the Existing Indebtedness, all on the
terms and conditions set forth below.

           ACCORDINGLY, in consideration of the foregoing premises, and the
representations, warranties and covenants contained herein, and for other good
and valuable consideration, the receipt and sufficiency of which hereby is
acknowledged, Zeitouni and the Company agree as follows:

           1.     Termination of Employment Agreement.
                  -----------------------------------

                  (a)  The employment of Zeitouni by the Company is terminated
effective as of the date hereof.

                  (b)  The rights and obligations of Zeitouni and the Company
under Employment Agreement are terminated, effective as of the date hereof. From
and after the date hereof, except as expressly provided in Section 1(f), neither
Zeitouni nor the Company shall have any further rights or obligations whatsoever
under the Employment Agreement.

                  (c)  Concurrently with the execution and delivery of this
Agreement, the Company shall pay to Zeitouni $32,000.80, the receipt of which
hereby is acknowledged by Zeitouni, in full payment of all amounts payable to
Zeitouni by the Company pursuant to the Employment Agreement less all applicable
state and federal withholding taxes.

<PAGE>

        (d) Zeitouni acknowledges and agrees that, except as set forth in
Section 1(c) above, Zeitouni is not entitled to any additional compensation or
benefits (including, but not limited to, vacation pay, sick pay, severance pay
or any other benefit) as a result of, in connection with or related to his
employment by the Company, whether pursuant to the Employment Agreement or
otherwise. Notwithstanding the foregoing, the Company shall offer to Zeitouni
the continuation of health insurance coverage to the extent required by the
Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA), the cost of
which shall be borne by Zeitouni.

        (e) Zeitouni agrees to return to an executive officer of the Company
promptly after the date hereof all property of the Company in the custody or
control of Zeitouni, including, but not limited to, all office equipment, forms,
manuals, documents or other material.

        (f) Notwithstanding anything to the contrary contained in this
Agreement, Sections 8.1, 9 and 10 of the Employment Agreement shall remain in
full force and effect; provided, however, that (i) the termination of employment
                       --------
in Section 1(a) of this Agreement shall not be deemed a termination as set forth
in clause (i) of Section 9 of the Employment Agreement, and (ii) the only
business or enterprise competitive with the Company to which Section 9 of the
Employment Agreement shall apply is The Gap, Inc. and its affiliates.

     2. Consulting Services.
        -------------------

        (a) The Company hereby retains Zeitouni as a consultant, and Zeitouni
hereby accepts such appointment, on the terms and conditions set forth below, to
perform during the period commencing on October 1, 2001 and ending on December
31, 2002 such services as are required hereunder.

        (b) Zeitouni shall render such services to the Company, and shall
perform such duties and acts, as reasonably may be requested by the Company in
connection with (i) the development of policy and strategy, (ii) assuring the
smooth transition of his responsibilities and (iii) marketing, client relations
and public relations; provided, however, that in no event shall Zeitouni be
                      --------  -------
required to devote more than ten (10) hours in any calendar month to the
performance of his duties under this Agreement.

        (c) Zeitouni shall devote such time, ability and attention to the
Company's business as Zeitouni may deem to be necessary or advisable to
discharge his duties hereunder in a professional and businesslike manner.

        (d) Zeitouni shall be an independent contractor of the Company. Nothing
in this Agreement shall be construed to give Zeitouni any rights as an employee,
agent, partner or joint venturer of the Company or to entitle Zeitouni to
control in any manner the business of the Company or to incur any debt,
liability or obligation on behalf of the Company.

        (e) As the total consideration for the services that Zeitouni renders
under this Section 2, Zeitouni shall be entitled to a monthly consulting fee of
$11,666.66,

                                      -2-

<PAGE>

without any deduction therefrom for income tax or other applicable withholdings,
payable on the fifteenth day of each month commencing on October 15, 2001
and ending on December 15, 2002, or the next business day if such fifteenth day
shall not be a business day.

        3.      Mortgage. For so long as Zeitouni is not in default of any
                --------
provision of this agreement, the Company shall pay to Zeitouni $4,400 on the
first day of each month, commencing on November 1, 2001 and ending on the
earlier to occur of the Closing Date (as defined in the Option Agreement) and
March 31, 2003, in partial payment of Zeitouni indebtedness incurred in
connection with Zeitouni's purchase of those premises commonly known as 48
Pleasant Place, Deal, New Jersey 07723 (the "Premises"). If Zeitouni sells,
transfers or assigns any interest in the Premises, he immediately shall notify
the Company of the transaction and the obligation of the Company to make any
payment to Zeitouni under this Section 3 immediately shall cease. Subject to
Section 5(f), $3,500 of each $4,400 monthly payment made by the Company to
Zeitouni under this Section 3 shall be due and payable on the earlier to occur
of the Closing Date (as defined in the Option Agreement) or March 31, 2003.

        4.      Indebtedness.
                ------------

                (a) Zeitouni acknowledges and agrees that as of the date hereof
he is indebted to the Company in the amount of $738,500.00 for funds heretofore
advanced to him by the Company (the "Existing Indebtedness"), which, subject to
Section 5(f), is due and payable on the earlier to occur of the Closing Date
(as defined in the Option Agreement) or March 31, 2003.

                (b) The Company agrees to advance to Zeitouni an additional
$300,000, receipt of which hereby is acknowledged (the "Advance"), which,
subject to Section 5(f), is due and payable on the earlier to occur of the
Closing Date (as defined in the Option agreement) or March 31, 2003.

        5.      Amendment of Put Option.
                -----------------------

                (a) Section 1.1 of the Option Agreement is amended to read in
full as follows:

        The Company hereby grants to GMC and RAI (each an
        "Optionholder") the right (the "Put Option") to
        require the Company to purchase all or any part
        of the Shares at the rate of $18.54 per Share at
        any time or from time to time during the three
        month period commencing on January 1, 2003 and
        ending on March 31, 2003.

                (b) The second sentence of Section 1.3 of the Option agreement
is amended to read in full as follows:

        On the Closing Date, the Company shall deliver to
        the Optionholder the purchase price for the Shares
        to be purchased by the Company, less any indebtedness
        of the Optionholder to

                                      -3-

<PAGE>

          the Company then owing, and the Optionholder shall deliver to the
          Company certificates evidencing such Shares properly endorsed for
          transfer.

               (c) If the Company fails to pay any amount due to Zeitouni under
this Agreement within ten (10) days of a written demand therefor, Zeitouni shall
have the right to immediately exercise the Put Option in the manner set forth in
the Option Agreement.

               (d) The parties acknowledge that the Optionholders (as defined in
the Option Agreement) have transferred and delegated to Zeitouni, and Zeitouni
has accepted and assumed, all rights and duties of the Optionholders under the
Option Agreement.

               (e) Zeitouni acknowledges and agrees that upon the exercise of
the Put Option (as defined in the Option Agreement) any purchase price then
payable by the Company shall be offset by any indebtedness of Zeitouni to the
Company then outstanding, including, but not limited to, (i) the Existing
Indebtedness, (ii) the Advance and (iii) $3,500 of each $4,400 monthly payment
made by the Company to Zeitouni pursuant to Section 3 hereof (all such portions
of the monthly payments collectively, the "Mortgage Advance").

               (f) Notwithstanding anything to the contrary contained in this
Agreement, (i) Zeitouni shall not be required to repay any portion of the
Existing Indebtedness, the Advance or the amounts advanced under Section 3 until
the earlier to occur of the Closing Date (as defined in the Option Agreement) or
March 31, 2003, (ii) in the event Zeitouni shall properly exercise the Put
Option in the manner set forth in the Option Agreement and the Company shall
fail promptly thereafter to pay to Zeitouni the purchase price then payable to
him under the Option Agreement (less any indebtedness of Zeitouni to the Company
then outstanding), then the Put Option shall be cancelled and the Existing
Indebtedness, the Advance and the Mortgage Advance shall be forgiven to the
extent such amounts exceed in the aggregate the result obtained by multiplying
(x) the number of shares of the Company's Common Stock subject to the Put Option
by the difference between (y) $18.54 and (z) the greater of the last sale price
of the Company's Common Stock on the date such Put Option is exercised by
Zeitouni or the average price per share at which any such shares thereafter are
sold by Zeitouni, and (iii) the Company shall have no right to offset any
indebtedness of Zeitouni against any amount payable hereunder by the Company to
Zeitouni under Section 1(c), 2(e) or 3.

           6.  General Release.
               ---------------

               (a) Except as expressly set forth in this Agreement, each party
fully, forever and unconditionally releases, exonerates, waives, relinquishes,
discharges, acquits, relieves and covenants not to sue or charge the other
party and its agents, employees, representatives, attorneys, stockholders,
officers, directors, successors and assigns (collectively, "all related
persons"), and all affiliated, parent and subsidiary corporations, and each of
them, and all related persons connected therewith, from any and all rights,
claims, demands, debts, obligations, liabilities, promises, acts, agreements,
costs, expenses (including, but not limited to, attorneys' fees and costs),
damages, disputes, controversies, actions and causes of action, of whatever kind
or nature, in law or equity, whether known or unknown,

                                      -4-

<PAGE>

suspected or unsuspected, potential or actual, based on, arising out of or in
any way connected with or related to the employment of Zeitouni by the Company,
whether pursuant to the Employment Agreement or otherwise, or the termination of
such employment, including, but not limited to, any claims for breach of
contract or employment discrimination arising out of the California Fair
Employment and Housing Act, Title VII of the Civil Rights Act of 1964, the
Americans with Disabilities Act or the Age Discrimination in Employment Act.

               (b) The previous paragraph set forth above specifically includes
any and all claims, demands, obligations, and/or causes for compensatory and/or
exemplary damages and/or other relief relating to or in any way connected with
the terms, conditions and benefits of employment, including, without limitation,
workers' compensation benefits, emotional distress, disability, and other health
benefits, vacation pay, sick pay, age discrimination, and any other
discrimination, including, but not limited to, sex, national origin, race,
religion, handicap, and/or any other type of discrimination, whether or not
specifically or particularly described herein. Each party expressly waives any
right or claim of right to assert hereafter that any claim, demand, obligation
and/or cause of action has, through ignorance, oversight or error, been omitted
from the terms of this Agreement.

               (c) The release made by the Company in this Section 6 explicitly
excludes any and all claims, demands, obligations, and/or causes for
compensatory and/or exemplary damages and/or other relief relating to or in any
way connected with (i) willful misconduct; (ii) actions conducted without a good
faith belief that they were in the best interest of the Company; (iii) gross
negligence; or (iv) conduct that is criminal under the laws of any state or the
United States.

               (d) Except as expressly set forth in this Agreement, each party
acknowledges that no statement, representation, promise or inducement has been
made by the other in connection with this Agreement, and each party specifically
acknowledges that he has not relied upon any statement, representation, promise
or inducement of the other in executing this Agreement. This Agreement
supersedes all prior negotiations and understandings of any kind with respect to
the subject matter hereof and contains all of the agreement of the parties
hereto. There are no oral understandings not incorporated herein. This Agreement
shall not be amended, modified, supplemented or abrogated other than by a
written instrument duly executed by all parties hereto.

               (e) Each party understands and agrees that except as expressly
set forth in paragraph 6(c) this Section 6 extends to all claims of whatever
nature and kind, known and unknown, suspected or unsuspected, and expressly
waives any and all rights under (S) 1542 of the Civil Code of the State of
California, which provides as follows:

          A general release does not extend to claims which the creditor does
          not know or suspect to exist in his favor at the time of executing the
          release, which if known by him must have materially affected his
          settlement with the debtor.

Each party expressly waives and releases any right or benefit that it has or may
have under (S) 1542 of the Civil Code of the State of California, as well as
under the provisions of all

                                       -5-

<PAGE>

comparable or similar statutes, provisions of common law or other decisional law
of any and all states of the United States, to the full extent that it waives
all such rights and benefits pertaining to the matters released herein. In
connection with such waiver and relinquishment, each party acknowledges that it
may hereafter discover claims presently unknown or unsuspected, or facts in
addition to or different from those that he now knows or believes to be true,
with respect to the matters released herein. Nevertheless, it is the intention
of each party through this Agreement, fully, finally and forever to settle and
release all such matters, and all claims relative thereto, which do now exist,
may exist or heretofore have existed in connection with Zeitouni's employment by
the Company, whether pursuant to the Employment Agreement or otherwise. In
furtherance of such intention, the release herein given shall be and remain in
effect as a full and complete release of such matters notwithstanding the
discovery or existence of any such additional different claims or facts relative
thereto, and each party expressly assumes the risk of any injury, loss or damage
that may arise from this waiver.

     7.  Indemnification. The Company agrees to indemnify Zeitouni for
         ---------------
expenditures and losses incurred by him in direct consequence of the discharge
of his duties, or of his obedience to the directions of the Company, as provided
in Section 2802 of the California Labor Code.

     8.  Successors and Assigns. This Agreement shall inure to the benefit of,
         ----------------------
and shall be binding upon, the successors and assigns of the parties hereto.

     9.  Severability. In the event that any provision of this Agreement should
         ------------
be held to be void, voidable or unenforceable, the remaining provisions, and any
partially unenforceable provisions to the extent enforceable, shall remain in
full force and effect.

     10. Governing Law. This Agreement shall be construed in accordance with,
         -------------
and be governed by, the laws of the State of California applicable to contracts
made and to be performed wholly within that State.

     11. Attorneys' Fees. In the event any party takes legal action to enforce
         ---------------
any of the terms of this Agreement, the unsuccessful party to such action shall
pay the successful party's expenses, including reasonable attorneys' fees and
costs, incurred in such action.

     12. Counterparts. This Agreement may be executed simultaneously in two or
         ------------
more counterparts, each one of which shall be deemed an original, but all of
which shall constitute one and the same instrument.

     13. Survival of Representations, Warranties and Agreements. All
         ------------------------------------------------------
representations, warranties and agreements made by the parties hereto in this
Agreement (including, but not limited to, statements contained in any schedule
or certificate or other instrument delivered by or on behalf of any party hereto
or in connection with the transactions contemplated hereby) shall survive the
date hereof and any investigations, inspections, examinations or audits made by
or on behalf of any party.

                                      -6-

<PAGE>

     14. Entire Agreement. This Agreement constitues the entire agreement
         ----------------
between the parties hereto pertaining to the subject matter hereof, and
supersedes all prior agreements, understandings, negotiations and discussions,
whether oral or written, relating to the subject matter of this Agreement. No
supplement, modification, waiver or termination of this Agreement shall be valid
unless executed by the party to be bound thereby. No waiver of any of the
provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provisions hereof (whether or not similar), nor shall any such waiver
constitute a continuing waiver unless otherwise expressly provided.

     15. Notices. Any notice or other communication required or permitted
         -------
hereunder shall be in writing and shall be deemed to have been given (i) if
personally delivered, when so delivered, or (ii) if mailed, one (1) week after
having been placed in the mail, registered or certified, postage prepaid,
addressed to the party to whom it is directed at the address set forth below.
Either party may change the address to which such notices are to be addressed by
giving the other party notice in the manner herein set forth.

     16. Headings. Section and subsection headings are not to be considered part
         --------
of this Agreement and are included solely for convenience and reference and in
no way define, limit or describe the scope of this Agreement or the intent of
any provisions hereof.

     17. Third Parties. Nothing in this Agreement, expressed or implied, is
         -------------
intended to confer upon any person other than the parties hereto and their
successors and assigns any rights or remedies under or by reason of this
Agreement.

     18. Further Assurances. Each party hereto shall, from time to time at and
         ------------------
after the date hereof, execute and deliver such instruments, documents and
assurances and take such further actions as the other party may reasonably
request to carry out the purpose and intent of this Agreement.

     19. Arbitration. Any and all disputes, controversies or claims arising out
         -----------
of or related to this Agreement, including without limitation, those claims
released in Section 6, fraud in the inducement of this Agreement, or relating to
the general validity or enforceability of this Agreement, shall be filed in Los
Angeles, California and submitted to final and binding arbitration under the
auspices and rules of the Judicial Arbitration and Mediation Services, Inc., or
if it is no longer in existence, under the auspices and rules of the American
Arbitration Association. There shall be one arbitrator. The arbitrator shall be
a retired superior court of federal judge. The parties agree that they have
waived any right to trial by jury. The decision of the arbitrator shall be final
and binding and the judgement rendered may be entered in any court having
jurisdiction. The prevailing party in any such arbitration proceeding shall be
entitled to its costs and reasonable attorney's fees, costs and expenses. The
provisions of California Code of Civil Procedure Sections 1281, et. seq. govern
                                                                --  ---
this arbitration provision.

     20. Termination of Prior Agreements. Any provision of any agreement between
         -------------------------------
the parties hereto, including, but not limited to, the Employment Agreement,
which is inconsistent with the terms of this Agreement, shall be null and void
and of no force and effect to the extent inconsistent herewith.

                                      -7-

<PAGE>

          21.  Legal Counsel. EACH PARTY HEREBY ACKNOWLEDGES THAT IN CONNECTION
               -------------
WITH THIS AGREEMENT IT HAS SOUGHT THE ADVICE OF SUCH INDEPENDENT LEGAL COUNSEL
AS IT SHALL HAVE DETERMINED TO BE NECESSARY OR ADVISABLE IN ITS SOLE AND
ABSOLUTE DISCRETION.

          IN WITNESS WHEREOF, the parties hereto have caused this Consulting
Agreement to be executed as of the date and year first set forth above.

                                       TARRANT APPAREL GROUP

                                       By /s/ Gerard Guez
                                          ----------------------------------
                                            3151 E. Washington Boulevard
                                            Los Angeles, CA 90023

                                       /s/ Gabriel Zeitouni
                                       -------------------------------------
                                       GABRIEL ZEITOUNI
                                       1768 East 8th Street
                                       Brooklyn, New York 11223

                                      -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]